#USA #Indianapolis #Lilly #OSA #Foundayo

Major Breakthrough in Obstructive Sleep Apnea Treatment with Foundayo

Eli Lilly and Company has made significant strides in the management of obstructive sleep apnea (OSA) with its drug, Foundayo (orforglipron). According to the latest findings from the ATTAIN-OSA Phase 3 clinical trial, Foundayo has demonstrated impressive results in not only reducing the severity of sleep apnea but also in improving overall cardiovascular health for patients who are overweight or obese.

Background on Obstructive Sleep Apnea

Obstructive sleep apnea affects a staggering 936 million adults globally, with many remaining undiagnosed. This condition causes repeated breathing interruptions during sleep, leading to decreased oxygen levels and increased blood pressure, which are strongly associated with serious cardiovascular issues such as hypertension, heart failure, and even strokes.

Recognizing the critical relationship between sleep disturbances and cardiovascular health, the American Heart Association emphasizes the importance of treating OSA as part of comprehensive cardiovascular care.

Exciting Findings from ATTAIN-OSA

In the 52-week study involving adults with moderate-to-severe OSA, Foundayo met its primary endpoint by achieving a substantial reduction in the apnea-hypopnea index (AHI) – a key measure of sleep apnea severity. Participants not using positive airway pressure (PAP) therapy experienced a remarkable 43.8% decrease in AHI events, with many showing significant improvement in their overall health outcomes.

Notably, 47.2% of these participants achieved a reduction in AHI of 50% or more, and nearly one-third (31.5%) reached remission or mild OSA status. Even those on PAP therapy saw an AHI reduction of 27.5%, showcasing Foundayo's effectiveness across varying treatment backgrounds.

Additionally, participants reported an impressive average weight loss of 28 pounds, which further contributed to the positive health indicators observed in the study. The drug also notably decreased sleep apnea-specific hypoxic burden, resulting in higher oxygen levels during sleep, alongside improvements in critical cardiovascular risk factors.

Improved Cardiovascular Outcomes

Dr. Vaishnavi Kundel, an Associate Professor in Pulmonary and Critical Care Medicine, noted the two-way relationship between sleep health and cardiovascular well-being, emphasizing that Foundayo significantly reduces oxygen deprivation and enhances blood pressure levels. Along with improving sleep quality, the drug exhibited promising results in mitigating inflammation and other cardiovascular risk markers.

Future Prospects for Foundayo

With plans to submit Foundayo to the U.S. FDA for approval as a treatment for moderate-to-severe OSA by the end of 2026, Eli Lilly is paving the way toward providing a multifaceted approach to managing both obesity and associated health complications.

Dr. Thomas Seck, Senior Vice President of Product Development at Lilly, remarks, "Obstructive sleep apnea is a severe complication of obesity and a key factor in cardiovascular disease. Foundayo has shown tremendous potential in treating these interconnected conditions, thereby improving the quality of life for affected individuals."

The overall safety profile of Foundayo was consistent with previous trials, indicating a generally tolerable side effect profile, primarily gastrointestinal in nature.

Conclusion

Lilly's innovative approach with Foundayo not only addresses weight loss but embraces a more comprehensive strategy to improve overall health for patients battling obesity-related conditions, paving the way for potentially significant advancements in the treatment landscape for disorders like obstructive sleep apnea. As the company moves forward with their FDA submissions, the hope is to enhance healthcare outcomes for millions.